CTLA4 and melanoma: We assessed the similarity of immune-related gene expression profiles between the TCGA-PDAC cohort and a cohort of 32 melanoma patients receiving sequential CTLA-4 and PD-1 inhibitors (Figures 8B, C) (37, 50).